Table 3.

Multivariable logistic regression identifying factors associated with female sexual dysfunction (FSFI total < 26.55)

Characteristic	OR (95% CI)	P value
Age, y
<30	Ref
30–39	1.65 (0.73–3.77)	.22
40–49	0.85 (0.37–2.02)	.71
50–59	1.76 (0.73–4.38)	.21
60+	1.28 (0.48–3.42)	.62
Race
White	Ref
Black	2.52 (0.69–8.3)	.14
Hispanic	0.51 (0.20–1.19)	.14
Other	1.71 (0.78–3.67)	.17
Relationship status
Married/relationship	Ref
Single	0.66 (0.33–1.27)	.23
Unknown	1.01 (0.05–9.08)	1.00
Region
West	Ref
International	0.66 (0.32–1.35)	.27
Midwest	0.36 (0.12–0.95)	.05
Northeast	0.63 (0.31–1.24)	.19
South	0.71 (0.36–1.40)	.34
BMI
Normal	Ref
Underweight	2.45 (0.43–11.85)	.28
Overweight	1.04 (0.57–1.85)	.91
Obese	0.94 (0.43–1.99)	.87
Extremely obese	1.12 (0.47–2.53)	.79
Tobacco use
Never	Ref
Current	0.48 (0.18–1.16)	.12
Former	1.04 (0.63–1.70)	.88
PCP visits in last 3 mo
0	Ref
1	1.33 (0.78–2.29)	.30
2+	0.99 (0.47–2.03)	.99
Cannabis use frequency (continuous)	0.79 (0.68–0.92)	.002∗
Method of consumption
Smoking flower	Ref
Edibles	1.42 (0.65–3.02)	.37
Other	1.06 (0.32–3.22)	.92
Smoking concentrates	1.63 (0.55–4.48)	.35
Tincture or oils	1.2 (0.57–2.52)	.62
Vaping	1.01 (0.48–2.05)	.99
Cannabinoid
THC dominant	Ref
Both THC and CBD	0.64 (0.38–1.09)	.10
CBD dominant	1.34 (0.58–3.05)	.49
Total comorbidities (continuous)	1.26 (1.05–1.52)	.02∗

BMI = body mass index; CBD = cannabidiol; FSFI = female sexual function index; OR = odds ratio; PCP = primary care physician; THC = tetrahydrocannabinol.

Comorbidities included hypertension, diabetes, heart disease, arthritis, lung disease, kidney disease, thyroid disease, hypercholesterolemia, cancer, neurologic disease, liver disease, depression, and anxiety.

Region represents primary residence.

^∗Significant (P < .05)